You are here:Home-Inhibitors & Agonists-JAK/STAT Signaling-STAT

Request The Product List ofSTAT STAT

Cat. No. Product Name CAS No. Information



FLLL-32 is a cell-permeable analog of curcumin that inhibits JAK2-mediated phosphorylation of STAT3 on Tyr705 in cancer cells (IC50=5 uM); induces apoptosis in pancreatic and breast cancer cell lines; also inhibit colony formation in soft agar and cell invasion and exhibits synergy with Doxorubicin against breast cancer cells; decreases STAT3 DNA binding activity and expression, and induces apoptosis in several cancer cell lines.


STAT5b inhibitor 7


STAT5b inhibitor 7 (Capstafin prodrug) is the pivaloyloxymethyl ester prodrug of Capstafin, which is a potent, selective STAT5b inhibitor with Ki of 0.34 uM; inhibits STAT5b with selectivity over STAT5a in human tumor cells, inhibits cell viability and induces apoptosis in human tumor cells in a STAT5-dependent manner.




Stafib-2 (Stafib 2) is a potent, selective small molecule inhibitor of transcription factor STAT5b with Ki of 9 nM, >20-fold selectivity over STAT5a.




SH5-07 (SH-5-07, SH 5-07) is a potent, selective small-molecule STAT3 inhibitor with IC50 of 3.9 uM; preferentially inhibits Stat3:Stat3 DNA-binding activity, shows no inhibition of Stat1:Stat1 or Stat5:Stat5 activity; exerts pY705 Stat3 inhibition in human glioma, breast, and prostate cancer cells, blocks STAT3-dependent gene transcription along with Bcl-2, Bcl-xL, Mcl-1, cyclin D1, c-Myc, and survivin expression; decreases the proliferation and viability of glioma, breast, and prostate cancer cells and v-Src-transformed murine fibroblasts harboring constitutively active STAT3; effectively inhibits tumor growth in mouse xenograft models of glioma and breast cancer.




Napabucasin (BBI-608) is a potent small-molecule inhibitor of STAT3 that has a broad spectrum of activity against stemness-high cancer cells (IC50=0.5-1.5 uM); blocks spherogenesis of cancer stem cells (CSC), but not hematopoietic stem cells; significantly reduces the expression of various stemness genes, including Nanog, Sox2, and Oct4 (POU5F1); significantly inhibits PaCa-2 xenograft tumor growth, and inhibits cancer relapse and metastasis.

Colon Cancer

Phase 3 Clinical



PM-43I is a selective inhibitor of STAT5/6 Src Homology 2 (SH2) domain, binds recombinant STAT6 and STAT5B (IC50=1.8 and 3.8 uM) with much lower affinity for STAT3 (IC50=29.9 uM); potently inhibits both STAT5- and STAT6-dependent allergic airway disease in mice; PM-43I reverses preexisting allergic airway disease in mice with a minimum ED50 of 0.25 μg/kg.


1090696-43-7 KI16 is a novel small molecules that inhibit STAT3-dependent transcription and function, interacts with the STAT3 SH2 domain; inhibits STAT3 phosphorylation and transcriptional activity in response to IL6 stimulation, inhibits cell viability preferentially in STAT3-dependent cell lines.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us